-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – FGF-1 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FGF-1 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FGF-1 in Parkinson's Disease Drug Details: FGF-1 is under development for the...
-
Product Insights
Venous Leg Ulcers (Crural Ulcer) – Drugs In Development, 2023
Global Markets Direct’s, ‘Venous Leg Ulcers (Crural Ulcer) - Drugs In Development, 2023’, provides an overview of the Venous Leg Ulcers (Crural Ulcer) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Venous Leg Ulcers (Crural Ulcer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Drugs In Development, 2023’, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Drugs In Development, 2023’, provides an overview of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Occlusive Arterial Disease (OAD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Occlusive Arterial Disease (OAD) - Drugs In Development, 2023’, provides an overview of the Occlusive Arterial Disease (OAD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Occlusive Arterial Disease (OAD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Peripheral Artery Occlusive Disease (PAOD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Peripheral Artery Occlusive Disease (PAOD) - Drugs In Development, 2023’, provides an overview of the Peripheral Artery Occlusive Disease (PAOD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peripheral Artery Occlusive Disease (PAOD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – FGF-1
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry FGF-1 Drug Details FGF-1 is under development for the treatment of Parkinson's disease, Alzheimer's...
-
Product Insights
Amyotrophic Lateral Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of amyotrophic lateral sclerosis include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss. The Amyotrophic Lateral Sclerosis pipeline market research report provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type....
-
Product Insights
Parkinson’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Parkinson's disease (PD) is a neurodegenerative disorder characterized by movement dysfunctions. The main finding in brains of people with PD is loss of dopaminergic neurons in substantia nigra. Symptoms generally develop slowly over years. People with PD experience dyskinesia, dystonia, tremor, stiffness and impaired locomotory functions. Risk factors include age, genetic factors, environmental factors and gender. Treatment options include anticholinergics, COMT inhibitors and dopamine agonists. The Parkinson’s disease pipeline drugs market research report provides comprehensive information on the therapeutics under...